Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

References

• BrayFLortet-TieulentJFerlayJFormanDAuvinenAProstate cancer incidence and mortality trends in 37 European countries: an overviewEur J Cancer201046173040305221047585
   PubMed Web of Science ®Google Scholar
• EisenbergerMABlumensteinBACrawfordEDBilateral orchiectomy with or without flutamide for metastatic prostate cancerN Engl J Med199833915103610429761805
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAOU-AA-301 InvestigatorsAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSCOU-AA-302 InvestigatorsAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFAFFIRM InvestigatorsIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• BeerTMArmstrongAJRathkopfDEPREVAIL InvestigatorsEnzalutamide in metastatic prostate cancer before chemotherapyN Engl J Med2014371542443324881730
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRTAX 327 InvestigatorsDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMTROPIC InvestigatorsPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDALSYMPCA InvestigatorsAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDIMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• JungMEOukSYooDStructure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)J Med Chem20105372779279620218717
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• GuerreroJAlfaroIEGómezFProtterAABernalesSEnzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancerProstate201373121291130523765603
   PubMed Web of Science ®Google Scholar
• XtandiHighlights of Prescribing InformationNorthbrook, ILAstellas Pharma US, Inc2015 Available from: http://www.astellas.us/docs/12A005-ENZ-WPI.PDFAccessed Jan 30, 2015
   Google Scholar
• ScherHIBeerTMHiganoCSProstate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials ConsortiumAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyLancet201037597241437144620398925
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMillerKEffect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialLancet Oncol201415101147115625104109
   PubMed Web of Science ®Google Scholar
• ScherHFizaziKSaadFAssociation of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI)Ann Oncol201223suppl 9 Abstr 899D
   Google Scholar
• ScherHIFizaziKSaadFImpact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitorJ Clin Oncol201331suppl 6 Abstr 6
   Web of Science ®Google Scholar
• SternbergCNde BonoJSChiKNImproved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialAnn Oncol201425242943424478320
   PubMed Web of Science ®Google Scholar
• HiganoCAlumkalJChowdhurySResponse rates and outcomes with enzalutamide for patients with metastatic castration-resistant prostate cancer and visceral disease in the PREVAIL trialAnn Oncol201425suppl 4 Abstr 767
   Google Scholar
• GraffJNBaciarelloGArmstrongAJClinical outcomes and safety in men ≥75 and <75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trialJ Clin Oncol201533suppl 7 Abstr 200
   Google Scholar
• SchraderAJBoegemannMOhlmannCHEnzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abirateroneEur Urol2014651303623849416
   PubMed Web of Science ®Google Scholar
• BianchiniDLorenteDRodriguez-VidaAAntitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneEur J Cancer2014501788424074764
   PubMed Web of Science ®Google Scholar
• SchmidSCGeithABökerAEnzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancerAdv Ther201431223424124442834
   PubMed Web of Science ®Google Scholar
• ThomsonDCharnleyNParikhOEnzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancerEur J Cancer20145051040104124462374
   PubMed Web of Science ®Google Scholar
• BadrisingSvan der NoortVvan OortIMClinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentCancer2014120796897524382803
   PubMed Web of Science ®Google Scholar
• ThomsenFBRøderMARathenborgPBrassoKBorreMIversenPEnzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetateScand J Urol201448326827524255983
   PubMed Web of Science ®Google Scholar
• BrassoKThomsenFBSchraderAJEnzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysisEur Urol Epub201486
   Web of Science ®Google Scholar
• Vera-BadilloFELeibowitz-AmitRTempletonAClinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: the Princess Margaret experienceJ Clin Oncol201432suppl 4 Abstr 159
   Google Scholar
• PetrelliFCoinuABorgonovoKEnzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case seriesClin Genitourin Cancer201513319319825466676
   PubMed Web of Science ®Google Scholar
• AzadAAEiglBJMurrayRNKollmannsbergerCChiKNEfficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patientsEur Urol2015671232925018038
   PubMed Web of Science ®Google Scholar
• SuzmanDLLuberBSchweizerMTNadalRAntonarakisESClinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abirateroneProstate201474131278128525053178
   PubMed Web of Science ®Google Scholar
• NadalRZhangZRahmanHClinical activity of enzalutamide in docetaxel-naïve and docetaxel-pretreated patients with metastatic castration-resistant prostate cancerProstate201474151560156825176007
   PubMed Web of Science ®Google Scholar
• ChengHHGulatiRAzadAActivity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxelProstate Cancer Prostatic Dis201518212212725600186
   PubMed Web of Science ®Google Scholar
• SmallEJRaymondLGardnerTASTRIDE, a randomized, phase 2, open-label study of sipuleucel-T with concurrent vs sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)Ann Oncol201425suppl 4 Abstr 774
   Google Scholar
• CellaDIvanescuCHolmstromSBuiCNSpaldingJFizaziKImpact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trialAnn Oncol201526117918525361992
   PubMed Web of Science ®Google Scholar
• LoriotYMillerKSternbergCNImpact of enzalutamide on skeletal-related events (SREs), pain and quality of life (QoL) in the PREVAIL trialAnn Oncol201425suppl 4 Abstr 762D
   Google Scholar
• ClaessensFHelsenCPrekovicSEmerging mechanisms of enzalutamide resistance in prostate cancerNat Rev Urol2014111271271625224448
   PubMed Web of Science ®Google Scholar
• AntonarakisESLuCWangHAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerN Engl J Med2014371111028103825184630
   PubMed Web of Science ®Google Scholar
• JosephJDLuNQianJA clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509Cancer Discov2013391020102923779130
   PubMed Web of Science ®Google Scholar
• KorpalMKornJMGaoXAn F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Cancer Discov2013391030104323842682
   PubMed Web of Science ®Google Scholar
• Rodriguez-VidaABianchiniDVan HemelrijckMIs there an antiandrogen withdrawal syndrome with enzalutamide?BJU Int2015115337338024906049
   PubMed Web of Science ®Google Scholar